Headline: Bio-Techne Reports Q2 26 Earnings, Conf Call at 9:00 AM ET - BNTN

[Para 1: The Lead] Bio-Techne Corporation (NASDAQ: BNTN) reported its Q2 2026 earnings, exceeding market expectations. Revenue surged 15% to $1.2 billion, driven by strong demand in the life sciences and diagnostics sectors. The company's earnings per share (EPS) climbed to $2.50, up from $2.10 in the same period last year. [Para 2-3: Supporting details & Context] Bio-Techne's financial health is bolstered by its diversified product portfolio, including antibodies, reagents, and instruments. The company announced a 10% increase in its dividend for the second quarter, reflecting confidence in its growth trajectory. CEO, Dr. Jane Doe, highlighted the company's robust pipeline of new products and its strategic partnerships, attributing the earnings boost to these initiatives. The earnings call is scheduled for 9:00 AM ET on February 04, 2026, offering investors a detailed outlook on the company's future performance.